Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines | Zendy

Takashi Yamatodani | Zendy; Lars Ekblad | Zendy; Elisabeth Kjellén | Zendy; Anders Johnsson | Zendy; Hiroyuki Mineta | Zendy; Johan Wennerberg | Zendy

Open Access

Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines

Author(s) -

Takashi Yamatodani,

Lars Ekblad,

Elisabeth Kjellén,

Anders Johnsson,

Hiroyuki Mineta,

Johan Wennerberg

Publication year - 2008

Publication title -

journal of cancer research and clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.338

H-Index - 94

eISSN - 1432-1335

pISSN - 0171-5216

DOI - 10.1007/s00432-008-0475-2

Subject(s) - cetuximab , epidermal growth factor receptor , head and neck squamous cell carcinoma , cancer research , mapk/erk pathway , protein kinase b , biology , epidermal growth factor , cell growth , cell cycle , growth factor receptor , medicine , phosphorylation , colorectal cancer , cancer , receptor , head and neck cancer , microbiology and biotechnology , genetics

The aim of this study was to investigate the effect of epidermal growth factor receptor (EGFR) blockade on cell survival and on downstream signalling pathways using the monoclonal antibody cetuximab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research